Cédric L.
- Country
- France
- Department
- oncology
Research Overview
- Evaluation of Oxaliplatin-Based Chemotherapy for Lean Body Mass Normalization in Patients with Colon Cancer
- PRODIGE 81-FFCD 2101-TRIPLET: Randomized, open-label, phase II-III study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patients with hepatocellular carcinoma receiving first-line systemic therapy
- Phase II Randomized Trial of Modified FOLFIRINOX and FOLFOX Regimens in Locally Advanced or Metastatic Small Bowel Adenocarcinoma
Data & Insights
Has run more than one trial at 176 of 298 partner sites.
Specializations
Colorectal Cancer Research
The investigator specializes in advancing treatment approaches for colorectal cancer, with particular focus on circulating tumor DNA analysis and personalized adjuvant therapy strategies.
- Stage II and III colon cancer management
- Molecular-guided treatment decisions
- KRAS G12C mutations
Research extends to elderly patient populations and innovative neoadjuvant approaches in locally advanced disease.
Gastrointestinal Oncology
Expertise encompasses various gastrointestinal malignancies, including gastroesophageal adenocarcinoma, small bowel adenocarcinoma, and pancreatic cancer.
- Treatment de-escalation strategies
- Advanced therapeutic protocols
- Chemotherapy optimization
Focus includes developing tailored approaches for different patient populations and disease stages.
Hepatobiliary Cancer
Investigates innovative treatments for hepatocellular carcinoma and biliary tract carcinoma, incorporating immunotherapy approaches.
- Immunotherapy combinations
- Adjuvant treatment strategies
- Novel therapeutic protocols
Research involves evaluation of targeted therapies and immunological approaches in liver and biliary cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.